28.17

2.18% 0.60

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $28.17, with a volume of 554.13K. It is up +2.18% in the last 24 hours and down -19.42% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Previous Close:

$27.57

Open:

$27.74

24h Volume:

554.13K

Relative Volume:

1.38

Market Cap:

$822.24M

Revenue:

$219.79M

Net Income/Loss:

$-57.47M

P/E Ratio:

-13.10

EPS:

-2.15

Net Cash Flow:

$-19.25M

1W Performance:

-8.63%

1M Performance:

-19.42%

6M Performance:

+22.00%

1Y Performance:

+26.72%

1-Day Range:

$27.40

$28.59

1-Week Range:

$26.61

$32.05

52-Week Range:

$14.59

$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1106)

Industry

Diagnostics & Research (52)

Phone

866-788-9007

Address

1500 W. PARKWOOD AVE., FRIENDSWOOD, TX

Employee

823

Twitter

@castlebio

Next Earnings Date

2024-11-04

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	28.17	804.73M	219.79M	-57.47M	-19.25M	-2.15
TMO Thermo Fisher Scientific Inc	512.69	190.90B	44.56B	6.73B	6.29B	17.74
DHR Danaher Corp	204.73	144.26B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	648.70	50.60B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	120.54	33.67B	6.95B	1.30B	1.15B	4.5696
WAT Waters Corp	319.04	30.62B	3.17B	642.63M	516.49M	10.77

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

Mar 04, 2026

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times

Mar 04, 2026

Melanoma test may let some patients skip lymph node surgery - Stock Titan

Mar 04, 2026

Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat

Mar 04, 2026

Mar 03, 2026

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget

Mar 03, 2026

CSTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Mar 02, 2026

Canaccord reiterates Castle Biosciences stock rating on Q4 beat By Investing.com - Investing.com India

Mar 02, 2026

Canaccord reiterates Castle Biosciences stock rating on Q4 beat - Investing.com

Mar 02, 2026

Mar 01, 2026

Aug Volume: What is the target price for Seer Inc stockEarnings Beat & Community Shared Stock Ideas - baoquankhu1.vn

Mar 01, 2026

Feb 28, 2026

Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus

Feb 28, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 28, 2026

Feb 27, 2026